Bristol Myers Squibb Defies Patent Cliff: Blockbuster Sales of Opdivo and Eliquis Drive Raised Forecast

BMS crushed Q3 goals and boosted its yearly forecast. New blockbusters like Opdivo and Eliquis cover losses from older generic drugs.